Hurel Corporation, a North Brunswick, NJ and Beverly Hills, CA-based provider of artificial tissue constructs and microfluidic cell-based assay platforms, raised $9.2m in Series A private equity financing.
The round was led by Spring Mountain, through its SMC Select Co-Investment Fund I, L.P., with participations from other private investor entities.
Led by CEO Robert Freedman, Hurel provides advanced artificial tissue constructs and microfluidic cell-based assay platforms that are used by major pharmaceutical research organizations in pre-clinical drug development, as well as in the toxicological testing of industrial materials and consumer products.
The company intends to use the capital for the commercial launch of its current products, the research and development of its technologies and future products, and other general corporate purposes.
FinSMEs
03/04/2013